If I was BTA management negotiating the ROW for LANI and GSK were the prime contender, as a condition for LANI ROW I would negotiate a higher Relenza royalty for the remaining unexpired term of the patent say 15% payable on and after the 30th June 2010, together with royalties at the same rate following expiration of the patent.
As to the ROW for LANI, no idea as DS will be in the driving seat on his one, and I presume that they will be fully aware of the earlier relenza royalty stoush between GSK and BTA
OR
- Forums
- ASX - By Stock
- BTA
- if i was bta management
if i was bta management
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)